{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T18:29:42Z","timestamp":1791916182024,"version":"4.3.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T00:00:00Z","timestamp":1693094400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T00:00:00Z","timestamp":1693094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"start-up funds for the introduction of talents from the First Affiliated Hospital of Xiamen University","award":["3502Z20214ZD3010"],"award-info":[{"award-number":["3502Z20214ZD3010"]}]},{"name":"Health Youth Scientific Research Project of Fujian Province","award":["2020QNB057"],"award-info":[{"award-number":["2020QNB057"]}]},{"name":"Health Youth Scientific Research Project of Fujian Province","award":["2021QNB015"],"award-info":[{"award-number":["2021QNB015"]}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2022J05304"],"award-info":[{"award-number":["2022J05304"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2020J011238"],"award-info":[{"award-number":["2020J011238"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2021J05291"],"award-info":[{"award-number":["2021J05291"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-023-02147-x","type":"journal-article","created":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T12:01:41Z","timestamp":1693137701000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["EZH2 inhibitor Tazemetostat synergizes with JQ-1 in esophageal cancer by inhibiting c-Myc signaling pathway"],"prefix":"10.1007","volume":"40","author":[{"given":"Nan","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abin","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senxia","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunping","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8254-755X","authenticated-orcid":false,"given":"Feng","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,27]]},"reference":[{"issue":"3","key":"2147_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"Cancer J Clin"},{"issue":"7330","key":"2147_CR2","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nature09784","volume":"469","author":"R Margueron","year":"2011","unstructured":"Margueron R, Reinberg D. The polycomb complex PRC2 and its mark in life. Nature. 2011;469(7330):343\u20139.","journal-title":"Nature"},{"issue":"1\u20132","key":"2147_CR3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.mrfmmm.2008.07.010","volume":"647","author":"JA Simon","year":"2008","unstructured":"Simon JA, Lange CA. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res. 2008;647(1\u20132):21\u20139.","journal-title":"Mutat Res"},{"issue":"1","key":"2147_CR4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1101\/gad.173930.111","volume":"26","author":"A He","year":"2012","unstructured":"He A, Shen X, Ma Q, et al. PRC2 directly methylates GATA4 and represses its transcriptional activity. Genes Dev. 2012;26(1):37\u201342.","journal-title":"Genes Dev"},{"issue":"4","key":"2147_CR5","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.molcel.2012.09.004","volume":"48","author":"JM Lee","year":"2012","unstructured":"Lee JM, Lee JS, Kim H, et al. EZH2 generates a methyl degron that is recognized by the DCAF1\/DDB1\/CUL4 E3 ubiquitin ligase complex. Mol Cell. 2012;48(4):572\u201386.","journal-title":"Mol Cell"},{"issue":"5","key":"2147_CR6","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/ni.3125","volume":"16","author":"M Gunawan","year":"2015","unstructured":"Gunawan M, Venkatesan N, Loh JT, et al. The methyltransferase Ezh2 controls cell adhesion and migration through direct methylation of the extranuclear regulatory protein talin. Nat Immunol. 2015;16(5):505\u201316.","journal-title":"Nat Immunol"},{"issue":"6","key":"2147_CR7","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.ccr.2013.04.008","volume":"23","author":"E Kim","year":"2013","unstructured":"Kim E, Kim M, Woo DH, et al. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell. 2013;23(6):839\u201352.","journal-title":"Cancer Cell"},{"issue":"6113","key":"2147_CR8","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1126\/science.1227604","volume":"338","author":"K Xu","year":"2012","unstructured":"Xu K, Wu ZJ, Groner AC, et al. EZH2 oncogenic activity in castration-resistant prostate cancer cells is polycomb-independent. Science. 2012;338(6113):1465\u20139.","journal-title":"Science"},{"issue":"10","key":"2147_CR9","doi-asserted-by":"publisher","first-page":"2808","DOI":"10.1016\/j.celrep.2018.11.035","volume":"25","author":"J Kim","year":"2018","unstructured":"Kim J, Lee Y, Lu X, et al. Polycomb- and methylation-independent roles of EZH2 as a transcription activator. Cell Rep. 2018;25(10):2808\u20132820e2804.","journal-title":"Cell Rep"},{"issue":"8","key":"2147_CR10","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1515\/hsz-2019-0436","volume":"401","author":"SL Nutt","year":"2020","unstructured":"Nutt SL, Keenan C, Chopin M, et al. EZH2 function in immune cell development. Biol Chem. 2020;401(8):933\u201343.","journal-title":"Biol Chem"},{"issue":"13","key":"2147_CR11","doi-asserted-by":"publisher","first-page":"3480","DOI":"10.1016\/j.celrep.2018.03.002","volume":"22","author":"T Ito","year":"2018","unstructured":"Ito T, Teo YV, Evans SA, et al. Regulation of Cellular Senescence by polycomb chromatin modifiers through distinct DNA damage- and histone methylation-dependent pathways. Cell Rep. 2018;22(13):3480\u201392.","journal-title":"Cell Rep"},{"key":"2147_CR12","doi-asserted-by":"publisher","first-page":"947","DOI":"10.2741\/4760","volume":"24","author":"A Batool","year":"2019","unstructured":"Batool A, Jin C, Liu YX. Role of EZH2 in cell lineage determination and relative signaling pathways. Front bioscience (Landmark edition). 2019;24:947\u201360.","journal-title":"Front bioscience (Landmark edition)"},{"issue":"6907","key":"2147_CR13","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/nature01075","volume":"419","author":"S Varambally","year":"2002","unstructured":"Varambally S, Dhanasekaran SM, Zhou M, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 2002;419(6907):624\u20139.","journal-title":"Nature"},{"issue":"4","key":"2147_CR14","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1158\/1078-0432.CCR-05-1533","volume":"12","author":"K Collett","year":"2006","unstructured":"Collett K, Eide GE, Arnes J, et al. Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin Cancer Res. 2006;12(4):1168\u201374.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2147_CR15","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1200\/JCO.2005.01.5180","volume":"24","author":"IM Bachmann","year":"2006","unstructured":"Bachmann IM, Halvorsen OJ, Collett K, et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol. 2006;24(2):268\u201373.","journal-title":"J Clin Oncol"},{"issue":"20","key":"2147_CR16","doi-asserted-by":"publisher","first-page":"11606","DOI":"10.1073\/pnas.1933744100","volume":"100","author":"CG Kleer","year":"2003","unstructured":"Kleer CG, Cao Q, Varambally S, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A. 2003;100(20):11606\u201311.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2147_CR17","doi-asserted-by":"crossref","unstructured":"Liu F, Gu L, Cao Y et al. Aberrant overexpression of EZH2 and H3K27me3 serves as poor prognostic biomarker for esophageal squamous cell carcinoma patients. Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 2016, 21(1):80\u201390.","DOI":"10.3109\/1354750X.2015.1118537"},{"issue":"3","key":"2147_CR18","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1158\/2159-8290.CD-NB2020-006","volume":"10","author":"EZH2 First","year":"2020","unstructured":"First EZH2. Inhibitor approved-for Rare Sarcoma. Cancer Discov. 2020;10(3):333\u20134.","journal-title":"Cancer Discov"},{"issue":"5","key":"2147_CR19","first-page":"513","volume":"80","author":"SM Hoy","year":"2020","unstructured":"Hoy SM, Tazemetostat. First Approval Drugs. 2020;80(5):513\u201321.","journal-title":"First Approval Drugs"},{"key":"2147_CR20","doi-asserted-by":"publisher","first-page":"102154","DOI":"10.1016\/j.ctrv.2021.102154","volume":"94","author":"MJ Duffy","year":"2021","unstructured":"Duffy MJ, O\u2019Grady S, Tang M, et al. MYC as a target for cancer treatment. Cancer Treat Rev. 2021;94:102154.","journal-title":"Cancer Treat Rev"},{"issue":"26","key":"2147_CR21","doi-asserted-by":"publisher","first-page":"E2721","DOI":"10.1073\/pnas.1406722111","volume":"111","author":"J Bhadury","year":"2014","unstructured":"Bhadury J, Nilsson LM, Veppil Muralidharan S, et al. BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in myc-induced murine lymphoma. Proc Natl Acad Sci U S A. 2014;111(26):E2721\u20132730.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2147_CR22","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.58.3.10","volume":"58","author":"TC Chou","year":"2006","unstructured":"Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58(3):621\u201381.","journal-title":"Pharmacol Rev"},{"issue":"14","key":"2147_CR23","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.7150\/ijbs.45886","volume":"16","author":"N Ding","year":"2020","unstructured":"Ding N, You A, Tian W, et al. Chidamide increases the sensitivity of non-small cell Lung Cancer to Crizotinib by decreasing c-MET mRNA methylation. Int J Biol Sci. 2020;16(14):2595\u2013611.","journal-title":"Int J Biol Sci"},{"issue":"18","key":"2147_CR24","doi-asserted-by":"publisher","first-page":"4995","DOI":"10.7150\/thno.26627","volume":"8","author":"Z Huang","year":"2018","unstructured":"Huang Z, Zhou W, Li Y, et al. Novel hybrid molecule overcomes the limited response of solid tumours to HDAC inhibitors via suppressing JAK1-STAT3-BCL2 signaling. Theranostics. 2018;8(18):4995\u20135011.","journal-title":"Theranostics"},{"issue":"1","key":"2147_CR25","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12943-022-01539-3","volume":"21","author":"ST Xue","year":"2022","unstructured":"Xue ST, Zheng B, Cao SQ, et al. Long non-coding RNA LINC00680 functions as a ceRNA to promote esophageal squamous cell carcinoma progression through the miR-423-5p\/PAK6 axis. Mol Cancer. 2022;21(1):69.","journal-title":"Mol Cancer"},{"issue":"1","key":"2147_CR26","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1002\/ijc.25031","volume":"127","author":"LR He","year":"2010","unstructured":"He LR, Liu MZ, Li BK, et al. High expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy. Int J Cancer. 2010;127(1):138\u201347.","journal-title":"Int J Cancer"},{"issue":"1","key":"2147_CR27","first-page":"99","volume":"35","author":"HR Wang","year":"2015","unstructured":"Wang HR, Wang MH, Lian GY, et al. [Expression of enhancer of zeste homolog 2 in esophageal squamous cell carcinoma and its prognostic value in postoperative patients]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University. 2015;35(1):99\u2013102.","journal-title":"Nan fang yi ke da xue xue bao = Journal of Southern Medical University"},{"issue":"2","key":"2147_CR28","first-page":"345","volume":"38","author":"A Yamada","year":"2011","unstructured":"Yamada A, Fujii S, Daiko H, et al. Aberrant expression of EZH2 is associated with a poor outcome and P53 alteration in squamous cell carcinoma of the esophagus. Int J Oncol. 2011;38(2):345\u201353.","journal-title":"Int J Oncol"},{"issue":"4","key":"2147_CR29","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/s41388-018-0459-x","volume":"38","author":"J Sun","year":"2019","unstructured":"Sun J, Cai X, Yung MM, et al. miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer. Oncogene. 2019;38(4):564\u201380.","journal-title":"Oncogene"},{"issue":"10","key":"2147_CR30","doi-asserted-by":"publisher","first-page":"4202","DOI":"10.1182\/blood-2008-03-147645","volume":"112","author":"S Sander","year":"2008","unstructured":"Sander S, Bullinger L, Klapproth K, et al. MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood. 2008;112(10):4202\u201312.","journal-title":"Blood"},{"issue":"4","key":"2147_CR31","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1128\/MCB.06148-11","volume":"32","author":"F Neri","year":"2012","unstructured":"Neri F, Zippo A, Krepelova A, et al. Myc regulates the transcription of the PRC2 gene to control the expression of developmental genes in embryonic stem cells. Mol Cell Biol. 2012;32(4):840\u201351.","journal-title":"Mol Cell Biol"},{"issue":"3","key":"2147_CR32","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/bfgp\/elt007","volume":"12","author":"I Barbieri","year":"2013","unstructured":"Barbieri I, Cannizzaro E, Dawson MA. Bromodomains as therapeutic targets in cancer. Brief Funct Genomics. 2013;12(3):219\u201330.","journal-title":"Brief Funct Genomics"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-023-02147-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-023-02147-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-023-02147-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T03:43:30Z","timestamp":1695959010000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-023-02147-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,27]]},"references-count":32,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["2147"],"URL":"https:\/\/doi.org\/10.1007\/s12032-023-02147-x","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,27]]},"assertion":[{"value":"29 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the Xiamen University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"281"}}